Author

Irina Kryachok

Observed names: I Kryachok, I. Kryachok, I. А. Kryachok, I.A. Kryachok, Irina Anatol'evna Kryachok, Kryachok, Irina, І. A. Kryachok

Observed institutions: Tufts Medical Center, University of California, San Francisco, Zaporizhzhia State Medical and Pharmaceutical University, National Cancer Institute, National Cancer Institute, National Cancer Institute, National Academy of Medical Sciences of Ukraine, American University of Beirut

OpenAlex ID: A5052049559

Cancer and War in Ukraine

2022 · Sergey Kozhukhov, Nataliia Dovganych, et al. · JACC CardioOncology · 13

PDF

Impact of Different Induction Regimens on the Outcome of Primary Mediastinal B Cell Lymphoma in the Prospective Ielsg 37 Trial

2021 · M. Martelli, E. Zucca, et al. · Hematological Oncology · 13

PDF

Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.

2023 · Emanuele Zucca, Andrew Davies, et al. · Journal of Clinical Oncology · 10

18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis

2021 · Tetiana Skrypets, Cristina Ferrari, et al. · Journal of Personalized Medicine · 6

PDF

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

2020 · Shambavi Richard, Ajai Chari, et al. · Blood · 6

Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

2020 · Holger Hebart, Paolo Ghia, et al. · 6

MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis

2018 · Olga Novosad, Tanya Skrypets, et al. · Klinicka onkologie · 6

PDF

Baseline Pet Radiomics Outperforms Clinical Risk Scores in Predicting Primary Mediastinal B‐cell Lymphoma Outcome: Insights From the Ielsg37 Study

2023 · L. Ceriani, L. Milan, et al. · Hematological Oncology · 5

DA-EPOCH-R VS R-CHOP in Patients with Primary Mediastinal Large B-Cell Lymphoma: Results of Prospective Randomized Ukrainian Multicenter Study

2020 · Yana Stepanishyna, Tetiana Skrypets, et al. · Blood · 5

Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Progression: Updated Prospective Study

2020 · Olga Novosad, Oleksandr Gorbach, et al. · Blood · 4

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

2020 · John Kuruvilla, Radhakrishnan Ramchandren, et al. · Blood · 4

Influence of exogenous, physiological and factors of chronic inflammatory process on indicators of disturbances of adaptive processes of the person

2020 · Irina Sokolovskaya, Irina Kryachok, et al. · French-Ukrainian Journal of Chemistry · 4

PDF

S101: Omission of Radiotherapy in Primary Mediastinal B-cell Lymphoma Patients Following Complete Metabolic Response to Standard Immunochemotherapy: Results of the Ielsg37 Randomised Trial (nct01599559)

2023 · Maurizio Martelli, Luca Ceriani, et al. · HemaSphere · 3

A Randomized Trial of Observation Versus Radiotherapy in Primary Mediastinal B‐cell Lymphoma Patients With Complete Metabolic Response After Standard Immunochemotherapy

2023 · A. J. Davies, E. Zucca, et al. · Hematological Oncology · 3

PDF

Subtypes of Mature T and Nk Cell Lymphomas According to 2016 Who Classification. Preliminary Report of the International Prospective T‐cell Project 2.0

2021 · M Federico, C. S Chiattone, et al. · Hematological Oncology · 3

Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study

2020 · Holger W Auner, Maria Gavriatopoulou, et al. · Blood · 3

Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report

2020 · Udvardy Miklos, Vladimir Strugov, et al. · British Journal of Haematology · 3

PDF

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

2020 · Maria Mateos, Sundar Jagannath, et al. · Blood · 2

PET/CT Imaging of Lymphoma Outside the Western World

2021 · Raoul Gabus, Astrid Pavlovsky, et al. · Lymphoma · 1

PDF

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

2020 · Maria Mateos, Maria Gavriatopoulou, et al. · Blood · 1

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

2018 · Udvardy Miklos, Vladimir Strugov, et al. · Blood · 1

The role of indoleamine 2,3-dioxygenase expression in diffuse large B-cell lymphoma prognosis

2016 · I. Kryachok, T. Skrypets, et al. · Annals of Oncology · 1

Intermediate Results of Treatment of Primary Mediastinal Large В-Cell Lymphoma with Da-Epoch-R Regimen

2014 · I. Stepanishyna, I. Kryachok, et al. · Annals of Oncology · 1

Real-world Insights Into Clinical Features and Outcomes in Extranodal T-cell Lymphomas: Results From the International T-cell Project 2.0 Prospective Cohort Study.

2026 · Bushuieva, Maryna, Conte, Luana, et al.

884 | the Emotional Burden of Lymphoma: How Lymphoma Survivors Perceive Relationships and Self‐image

2025 · N. Shokun, Y. Stepanishyna, et al. · Hematological Oncology

PDF

Works count: 44

Citation count: 104

H-index: 6

I10-index: 3